美国透析患者磷结合剂使用:患病率、费用、证据与政策
2015年美国透析及CKD患者磷结合剂Medicare费用超15亿美元,且Part D矿物骨代谢药物费用增速快于所有Part D药物。尽管广泛使用且费用攀升,缺乏确凿证据表明磷结合剂改善透析或非透析CKD患者重要临床终点。利用USRDS和CMS CROWNWeb数据更新使用趋势、钙磷值及费用,并讨论疗效、安全性、比较效果与成本效果证据,建议FDA发布新磷结合剂临床评估指南,CMS资助临床试验评估不同磷酸盐浓度及特定磷结合剂对硬临床结局的影响。
要点
- 2015年磷结合剂Medicare费用超15亿美元,Part D矿物骨代谢药物费用增速快于所有Part D药物。
- 缺乏确凿证据表明磷结合剂改善透析或非透析CKD患者重要临床终点。
- 建议FDA发布新磷结合剂临床评估指南,CMS资助临床试验评估磷酸盐浓度及磷结合剂对硬结局的影响。
核心结论
- 尽管磷结合剂广泛使用且费用攀升,缺乏确凿证据表明其改善透析或非透析CKD患者重要临床终点。
研究设计与样本
- 利用USRDS透析患者数据和CMS CROWNWeb实验室信息更新磷结合剂使用趋势、钙磷值及费用,并结合临床试验、Meta分析和观察性研究证据讨论。
主要发现
- 2015年透析及CKD患者磷结合剂Medicare Part D费用超15亿美元。
- Part D矿物骨代谢药物费用增速快于所有Part D药物。
临床怎么用
- 临床应认识到磷结合剂改善硬临床结局的证据不足,关注费用与证据缺口。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Medicare costs for phosphate binders for US dialysis patients and patients with chronic kidney disease enrolled in Medicare Part D exceeded $1.5 billion in 2015. Previous data have shown that Part D costs for mineral and bone disorder medications increased faster than costs for all Part D medications for dialysis patients. Despite extensive use of phosphate binders and escalating costs, conclusive evidence is lacking that they improve important clinical end points in dialysis patients or non-dialysis-dependent patients with chronic kidney disease. Using dialysis patient data from the US Renal Data System and laboratory information from the Centers for Medicare & Medicaid Services (CMS) CROWNWeb data, we update information on trends in phosphate-binder use, calcium and phosphorus values, and costs for Medicare-covered dialysis patients. We discuss these results in the context of evidence from clinical trials, meta-analyses, and observational studies evaluating phosphate-binder efficacy, safety, comparative effectiveness, and cost-effectiveness. Based on our analysis, we note a need for US Food and Drug Administration guidance regarding clinical evaluation of new phosphate binders, and we suggest that it would be in CMS' best interest to fund a clinical trial to assess whether lower versus higher phosphate concentrations improve hard clinical outcomes, and if so, whether particular phosphate binders are superior to placebo or other binders in improving these outcomes.
引用
- St Peter WL, Wazny LD, Weinhandl ED, et al. Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies. Am J Kidney Dis. 2017. PMID: 29195858. doi:10.1053/j.ajkd.2017.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。